

## Supporting Information (SI)


### Table of Contents

|                                                                                        |            |
|----------------------------------------------------------------------------------------|------------|
| <b>1. General Information</b>                                                          | <b>S2</b>  |
| <b>2. General Procedure for the One-Pot Synthesis of Products 3</b>                    | <b>S3</b>  |
| <b>3. General procedure for the transformations of 3a</b>                              | <b>S4</b>  |
| <b>4. Crystal structure of 3c</b>                                                      | <b>S5</b>  |
| <b>5. Characterization of substrates and Products</b>                                  | <b>S7</b>  |
| <b>6. Reference</b>                                                                    | <b>S27</b> |
| <b>7. <math>^1\text{H}</math> NMR, <math>^{13}\text{C}</math> NMR and HPLC Spectra</b> | <b>S28</b> |

## 1. General Information.


Unless otherwise specified, all one-pot reactions were carried out in an over-dried Schlenk tube equipped with a magnetic stir bar under nitrogen atmosphere. DCE and DCM was distilled from  $\text{CaH}_2$ ; THF and 1,4-dioxane were distilled from sodium; *o*-Enyne-amides **1**<sup>[1]</sup> and isatin-derived enals **2**<sup>[2]</sup> were synthesized according to the known literatures. All other reagents were obtained from commercial sources and utilized without further purification, if not stated otherwise. All melting points are uncorrected. The NMR spectra were recorded in  $\text{CDCl}_3$  on a 400 or 600 M Hz instrument with TMS as internal standard. Recorded shifts were reported in parts per million ( $\delta$ ) downfield from TMS. Data are represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b = broad), coupling constant ( $J$ , Hz) and integration. TLC was carried out with 0.2 mm thick silica gel plates (GF254). Visualization was accomplished by UV light. The column chromatography was hand packed with silica gel 60 (160-200 mesh). The products were additionally confirmed by HRMS. Mass spectra were obtained using ESI ionization.

## 2. General Procedure for the One-Pot Synthesis of Products 3.




In a dried and nitrogen filled Schlenk flask, a mixture of PPh<sub>3</sub>AuCl (2.5 mg, 0.005 mmol, 5.0 mol %), AgPF<sub>6</sub> (1.3 mg, 0.005mmol, 5.0 mol %) in DCE (1 mL) was stirred at room temperature under nitrogen for 15 mins to generate the gold catalyst. Immediately afterwards, ynamide (0.1 mmol, 1.0 eq.) was added to the above catalyst solution and stirred for 0.5 h to gain the intermediate. The chiral NHC (9.7 mg, 0.025 mmol, 25 mol%), AcOK (11.7 mg, 0.12 mmol, 1.2 eq.) and isatin-derived enal **2** (0.15 mmol, 1.5 eq.) were subsequently added to the mixture under nitrogen. After that the mixture was stirred at room temperature until the reaction was complete (12-24 h, monitored by TLC). The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography on silica gel using (PE:EA:DCM = 40:1:20 to 60:1:20) as eluent to afford the desired product **3**.

### 3. General procedure for the transformations of **3a**



To a solution of **3a** (33.2 mg, 0.05 mmol, 1.0 eq.) in DCM (1 mL) was added *m*-CPBA (15 mg, 0.085 mmol, 1.7 eq.) in portions. The reaction mixture was stirred at room temperature for 3 h until the reaction was complete (monitored by TLC). The mixture was concentrated under reduced pressure. The resulting crude residue was purified via column chromatography on silica gel (PE:EA = 5:1) to afford the desired spiroindolinone derivative **4a** with 68% (23.1 mg) yield.

#### 4. Crystal structure of **3c**



The single-crystal of **3c** was grown from the mixed solution of ethyl acetate and petrol ether (v:v = 1:4).

The X-ray source used for the single crystal X-ray diffraction analysis was GaK $\alpha$  ( $\lambda = 1.34139$ ), and the thermal ellipsoid was drawn at the 50% probability level.

#### Important Structural Data:


|                     |                                                                 |
|---------------------|-----------------------------------------------------------------|
| CCDC Number         | 2232000                                                         |
| Identification code | <b>3c</b>                                                       |
| Empirical formula   | C <sub>42</sub> H <sub>34</sub> N <sub>2</sub> O <sub>5</sub> S |
| Formula weight      | 678.77                                                          |
| Temperature/K       | 293(2)                                                          |
| Crystal system      | orthorhombic                                                    |
| Space group         | P2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>                   |
| a/Å                 | 10.9916(5)                                                      |
| b/Å                 | 13.2198(8)                                                      |
| c/Å                 | 23.8003(10)                                                     |
| $\alpha$ /°         | 90                                                              |

|                                               |                                                               |
|-----------------------------------------------|---------------------------------------------------------------|
| $\beta/^\circ$                                | 90                                                            |
| $\gamma/^\circ$                               | 90                                                            |
| Volume/ $\text{\AA}^3$                        | 3458.3(3)                                                     |
| Z                                             | 4                                                             |
| $\rho_{\text{calc}}/\text{g}/\text{cm}^3$     | 1.304                                                         |
| $\mu/\text{mm}^{-1}$                          | 0.143                                                         |
| F(000)                                        | 1424.0                                                        |
| Crystal size/ $\text{mm}^3$                   | $0.23 \times 0.12 \times 0.11$                                |
| Radiation                                     | MoK $\alpha$ ( $\lambda = 0.71073$ )                          |
| $2\Theta$ range for data collection/ $^\circ$ | 4.82 to 54.962                                                |
| Index ranges                                  | $-14 \leq h \leq 14, -17 \leq k \leq 17, -30 \leq l \leq 30$  |
| Reflections collected                         | 38329                                                         |
| Independent reflections                       | 7903 [ $R_{\text{int}} = 0.0528, R_{\text{sigma}} = 0.0418$ ] |
| Data/restraints/parameters                    | 7903/0/454                                                    |
| Goodness-of-fit on $F^2$                      | 1.062                                                         |
| Final R indexes [ $I \geq 2\sigma(I)$ ]       | $R_1 = 0.0429, wR_2 = 0.0902$                                 |
| Final R indexes [all data]                    | $R_1 = 0.0704, wR_2 = 0.1033$                                 |
| Largest diff. peak/hole / $e \text{\AA}^{-3}$ | 0.13/-0.24                                                    |
| Flack parameter                               | -0.11(9)                                                      |

## 5. Characterization Data of Compounds 3.

(4R,5R)-1'-Benzyl-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-

2',7(6H)-dione (3a)



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.18 (d,  $J$  = 8.3 Hz, 2H), 7.80 – 7.69 (m, 2H), 7.51 (d,  $J$  = 8.1 Hz, 2H), 7.42 (t,  $J$  = 7.6 Hz, 2H), 7.34 – 7.29 (m, 1H), 7.23 – 7.09 (m, 6H), 7.07 – 6.98 (m, 3H), 6.95 – 6.88 (m, 2H), 6.76 – 6.67 (m, 2H), 6.54 (d,  $J$  = 7.0 Hz, 1H), 6.31 (d,  $J$  = 7.7 Hz, 1H), 4.67 (d,  $J$  = 15.9 Hz, 1H), 4.52 (d,  $J$  = 15.9 Hz, 1H), 4.02 (s, 1H), 3.24 (d,  $J$  = 12.6 Hz, 1H), 2.57 (s, 3H), 2.15 (d,  $J$  = 12.6 Hz, 1H).

$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  175.38, 169.04, 152.84, 146.12, 141.69, 139.44, 135.68, 134.95, 134.64, 130.06, 130.01, 129.95, 129.87, 129.80, 128.85, 128.74, 128.52, 128.31, 127.89, 127.54, 126.98, 124.32, 123.65, 122.94, 121.22, 109.33, 106.63, 61.27, 47.30, 43.92, 43.85, 21.99.


HRMS (ESI) for  $\text{C}_{41}\text{H}_{33}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 665.2105, found 665.2096.

$[\alpha]_{\text{D}}^{25} = +27.25$  ( $c$  = 0.25 in  $\text{CHCl}_3$ ).

HPLC analysis: 96% e.e. (Chiralcel OD-H, 25:75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 9.8 min,  $R_t$  (minor) = 16.3 min.

(4R,5R)-1'-Benzyl-2-phenyl-4-(*p*-tolyl)-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-

2',7(6H)-dione (3b)



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.17 (d,  $J$  = 8.3 Hz, 2H), 7.77 – 7.70 (m, 2H), 7.51 (d,  $J$  = 8.1 Hz, 2H), 7.41 (t,  $J$  = 7.6 Hz, 2H), 7.31 (t,  $J$  = 7.4 Hz, 1H), 7.21 – 7.16 (m, 1H), 7.16 – 7.10 (m, 2H), 7.02 (td,  $J$  = 7.8, 1.1 Hz, 1H), 6.94 – 6.87 (m, 6H), 6.72 (d,  $J$  = 7.1 Hz, 2H), 6.51 (d,  $J$  = 7.1 Hz, 1H), 6.32 (d,  $J$  = 7.7

Hz, 1H), 4.74 (d,  $J = 16.0$  Hz, 1H), 4.49 (d,  $J = 16.0$  Hz, 1H), 3.97 (s, 1H), 3.23 (d,  $J = 12.6$  Hz, 1H), 2.57 (s, 3H), 2.28 (s, 3H), 2.13 (d,  $J = 12.5$  Hz, 1H).


$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  175.43, 169.08, 152.76, 146.08, 141.71, 139.34, 137.48, 135.66, 134.98, 131.55, 130.11, 130.08, 129.84, 129.80, 129.78, 129.21, 128.82, 128.76, 128.61, 128.25, 127.49, 127.06, 124.28, 123.62, 122.86, 121.48, 109.33, 106.69, 61.26, 46.80, 43.96, 43.84, 21.98, 21.22.

**HRMS** (ESI) for  $\text{C}_{42}\text{H}_{35}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 679.2261, found 679.2259.

$[\alpha]^{25}_{\text{D}} = +17.25$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 87 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 9.5 min,  $R_t$  (minor) = 13.5 min.

**(4R,5R)-1'-Benzyl-2-phenyl-4-(*m*-tolyl)-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3c)**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.17 (d,  $J = 8.3$  Hz, 2H), 7.75 (d,  $J = 7.3$  Hz, 2H), 7.51 (d,  $J = 8.1$  Hz, 2H), 7.42 (t,  $J = 7.7$  Hz, 2H), 7.31 (t,  $J = 7.4$  Hz, 1H), 7.18 (t,  $J = 7.3$  Hz, 1H), 7.13 (t,  $J = 7.4$  Hz, 2H), 7.06 – 6.98 (m, 3H), 6.95 – 6.88 (m, 2H), 6.86 – 6.83 (m, 1H), 6.82 (s, 1H), 6.70 (d,  $J = 7.3$  Hz, 2H), 6.54 (d,  $J = 7.4$  Hz, 1H), 6.30 (d,  $J = 7.8$  Hz, 1H), 4.71 (d,  $J = 16.1$  Hz, 1H), 4.52 (d,  $J = 16.1$  Hz, 1H), 3.94 (s, 1H), 3.23 (d,  $J = 12.6$  Hz, 1H), 2.57 (s, 3H), 2.16 (s, 3H), 2.15 (d,  $J = 12.6$  Hz, 1H).


$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  175.39, 169.13, 152.79, 146.06, 141.71, 139.37, 138.10, 135.63, 134.99, 134.55, 130.74, 130.07, 130.01, 129.85, 129.80, 128.83, 128.79, 128.72, 128.64, 128.38, 128.28, 127.50, 126.93, 126.78, 124.31, 123.65, 122.86, 121.34, 109.34, 106.67, 61.25, 47.19, 43.96, 43.79, 21.99, 21.56.

**HRMS** (ESI) for  $\text{C}_{42}\text{H}_{35}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 679.2261, found 679.2260.

$[\alpha]^{25}_{\text{D}} = +25.25$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 79 % e.e. (Chiralcel IA, 20:80 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 12.4 min,  $R_t$  (minor) = 27.9 min.

**(4R,5R)-1'-Benzyl-2-phenyl-4-(*o*-tolyl)-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3d)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.22 (d,  $J = 8.1$  Hz, 2H), 7.76 (d,  $J = 6.3$  Hz, 1H), 7.71 (d,  $J = 7.8$  Hz, 2H), 7.47 (d,  $J = 8.0$  Hz, 2H), 7.40 (t,  $J = 7.6$  Hz, 2H), 7.30 (d,  $J = 7.3$  Hz, 1H), 7.21 – 7.13 (m, 3H), 7.12 – 7.07 (m, 2H), 7.06 – 7.01 (m, 1H), 6.96 – 6.88 (m, 3H), 6.80 (d,  $J = 7.0$  Hz, 2H), 6.74 (s, 1H), 6.37 (d,  $J = 7.7$  Hz, 1H), 4.79 (d,  $J = 15.9$  Hz, 1H), 4.70 (s, 1H), 4.57 (d,  $J = 15.9$  Hz, 1H), 3.29 (d,  $J = 12.7$  Hz, 1H), 2.53 (s, 3H), 2.14 (d,  $J = 12.6$  Hz, 1H), 1.83 (s, 3H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  176.04, 169.14, 152.57, 145.98, 141.74, 139.10, 136.77, 135.62, 135.02, 133.42, 130.87, 130.11, 130.09, 129.88, 129.82, 129.70, 129.04, 128.87, 128.82, 128.78, 128.23, 127.66, 127.57, 127.13, 126.29, 124.26, 122.75, 121.73, 109.33, 107.06, 61.48, 44.54, 44.02, 41.09, 21.96, 20.05.

**HRMS** (ESI) for  $\text{C}_{42}\text{H}_{35}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 679.2261, found 679.2270.

$[\alpha]_D^{25} = +20.25$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 85% e.e. (Chiralcel IA, 20:80 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 12.1 min,  $R_t$  (minor) = 22.7 min.

**(4R,5R)-1'-Benzyl-4-(3-methoxyphenyl)-2-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3e)**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.18 (d,  $J = 8.2$  Hz, 2H), 7.75 (d,  $J = 7.4$  Hz, 2H), 7.52 (d,  $J = 8.1$  Hz, 2H), 7.42 (t,  $J = 7.7$  Hz, 2H), 7.31 (t,  $J = 7.4$  Hz, 1H), 7.20 – 7.13 (m, 3H), 7.07 – 7.01 (m, 2H), 6.93 (s, 1H), 6.91 (t,  $J = 7.6$  Hz, 1H), 6.76 (dd,  $J = 8.3, 2.0$  Hz, 1H), 6.73 (d,  $J = 7.3$  Hz, 2H), 6.69 (d,  $J = 7.6$  Hz,

<sup>1</sup>H), 6.54 – 6.49 (m, 2H), 6.34 (d, *J* = 7.8 Hz, 1H), 4.72 (d, *J* = 16.1 Hz, 1H), 4.53 (d, *J* = 16.1 Hz, 1H), 3.98 (s, 1H), 3.59 (s, 3H), 3.23 (d, *J* = 12.6 Hz, 1H), 2.56 (s, 3H), 2.15 (d, *J* = 12.6 Hz, 1H).


<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 175.40, 169.02, 159.39, 152.83, 146.13, 141.78, 139.41, 136.06, 135.65, 134.98, 130.02, 129.86, 129.80, 129.47, 128.87, 128.84, 128.74, 128.31, 127.52, 126.84, 124.31, 123.59, 122.88, 122.12, 121.18, 115.61, 113.66, 109.39, 106.64, 61.20, 55.18, 47.27, 43.98, 43.84, 21.95.

**HRMS** (ESI) for C<sub>42</sub>H<sub>35</sub>N<sub>2</sub>O<sub>6</sub>S<sup>+</sup> [M+H]<sup>+</sup> *m/z*: calcd 695.2210, found 695.2208.

[α]<sub>D</sub><sup>25</sup> = +14.75 (c = 0.25 in CHCl<sub>3</sub>).

**HPLC** analysis: 93 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min), *R*<sub>t</sub> (major) = 13.7 min, *R*<sub>t</sub> (minor) = 23.7 min.

**(4R,5R)-1'-Benzyl-4-(4-chlorophenyl)-2-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3f)**



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.18 (d, *J* = 8.2 Hz, 2H), 7.74 (d, *J* = 7.5 Hz, 2H), 7.51 (d, *J* = 8.1 Hz, 2H), 7.42 (t, *J* = 7.6 Hz, 2H), 7.32 (t, *J* = 7.3 Hz, 1H), 7.25 – 7.17 (m, 3H), 7.10 – 7.03 (m, 3H), 7.00 – 6.91 (m, 3H), 6.85 (s, 1H), 6.76 – 6.69 (m, 2H), 6.60 (d, *J* = 7.4 Hz, 1H), 6.41 (d, *J* = 7.8 Hz, 1H), 4.77 (d, *J* = 15.9 Hz, 1H), 4.49 (d, *J* = 15.9 Hz, 1H), 4.05 (s, 1H), 3.22 (d, *J* = 12.6 Hz, 1H), 2.56 (s, 3H), 2.15 (d, *J* = 12.6 Hz, 1H).


<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 175.12, 168.77, 152.91, 146.16, 141.69, 139.44, 135.61, 134.80, 133.95, 133.16, 131.26, 129.89, 129.81, 129.79, 129.75, 129.07, 128.87, 128.76, 128.71, 128.41, 127.71, 126.98, 124.28, 123.60, 123.08, 120.70, 109.44, 106.25, 61.00, 46.63, 43.87, 21.96.

**HRMS** (ESI) for C<sub>41</sub>H<sub>32</sub>ClN<sub>2</sub>O<sub>5</sub>S<sup>+</sup> [M+H]<sup>+</sup> *m/z*: calcd 699.1715, found 699.1711.

[α]<sub>D</sub><sup>25</sup> = +41.00 (c = 0.25 in CHCl<sub>3</sub>).

**HPLC** analysis: 89 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min), *R*<sub>t</sub> (major) = 10.8 min, *R*<sub>t</sub> (minor) = 17.4 min.

**(4R,5R)-1'-Benzyl-2-phenyl-8-tosyl-4-(4-(trifluoromethyl)phenyl)-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3g)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.18 (d,  $J$  = 8.2 Hz, 2H), 7.74 (d,  $J$  = 7.4 Hz, 2H), 7.51 (d,  $J$  = 8.1 Hz, 2H), 7.42 (t,  $J$  = 7.6 Hz, 2H), 7.37 – 7.30 (m, 3H), 7.23 – 7.19 (m, 1H), 7.18 – 7.12 (m, 4H), 7.08 (t,  $J$  = 7.5 Hz, 1H), 6.96 (t,  $J$  = 7.5 Hz, 1H), 6.82 (s, 1H), 6.76 (d,  $J$  = 7.2 Hz, 2H), 6.64 (d,  $J$  = 7.4 Hz, 1H), 6.42 (d,  $J$  = 7.8 Hz, 1H), 4.75 (d,  $J$  = 15.8 Hz, 1H), 4.48 (d,  $J$  = 15.8 Hz, 1H), 4.12 (s, 1H), 3.23 (d,  $J$  = 12.6 Hz, 1H), 2.57 (s, 3H), 2.16 (d,  $J$  = 12.6 Hz, 1H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  175.10, 168.70, 153.08, 146.23, 141.61, 139.50, 138.78, 135.61, 134.83, 129.84, 129.83, 130.31, 129.98, 129.84, 129.83, 129.56, 129.22, 128.90, 128.79, 128.50, 127.84, 127.07, 125.40 (q,  $J$  = 3.6 Hz), 124.34, 123.61, 123.20, 120.43, 109.51, 106.14, 60.95, 47.07, 44.06, 44.03, 22.00.

**HRMS** (ESI) for  $\text{C}_{42}\text{H}_{32}\text{F}_3\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 733.1979, found 733.1969.

$[\alpha]_D^{25} = +23.25$  ( $c$  = 0.25 in  $\text{CHCl}_3$ ).

**HPLC** analysis: 86 % e.e. (Chiralcel IA, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 9.9 min,  $R_t$  (minor) = 28.7 min.

**(4R,5R)-1'-Benzyl-4-(4-nitrophenyl)-2-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3h)**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.19 (d,  $J$  = 7.8 Hz, 2H), 7.84 (d,  $J$  = 8.2 Hz, 2H), 7.74 (d,  $J$  = 7.7 Hz, 2H), 7.52 (d,  $J$  = 7.8 Hz, 2H), 7.43 (t,  $J$  = 7.4 Hz, 2H), 7.34 (t,  $J$  = 7.2 Hz, 1H), 7.24 – 7.20 (m, 1H), 7.19 – 7.11 (m, 5H), 7.00 (t,  $J$  = 7.5 Hz, 1H), 6.85 – 6.78 (m, 3H), 6.72 (d,  $J$  = 7.3 Hz, 1H), 6.52 (d,  $J$  = 7.8

Hz, 1H), 4.67 (d,  $J$  = 15.7 Hz, 1H), 4.49 (d,  $J$  = 15.6 Hz, 1H), 4.21 (s, 1H), 3.22 (d,  $J$  = 12.7 Hz, 1H), 2.57 (s, 3H), 2.18 (d,  $J$  = 12.8 Hz, 1H).


$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  174.78, 168.51, 153.17, 147.45, 146.31, 141.91, 141.58, 139.58, 135.53, 134.85, 130.81, 129.85, 129.81, 129.69, 129.46, 129.36, 128.94, 128.71, 128.62, 128.12, 127.42, 124.33, 123.71, 123.44, 123.40, 119.76, 109.39, 105.82, 60.74, 47.18, 44.00, 43.85, 22.02.

**HRMS** (ESI) for  $\text{C}_{41}\text{H}_{32}\text{N}_3\text{O}_7\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 710.1955, found 710.1952.

$[\alpha]^{25}_{\text{D}} = +14.75$  ( $c$  = 0.25 in  $\text{CHCl}_3$ ).

**HPLC** analysis: 85 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 22.7 min,  $R_t$  (minor) = 28.7 min.

**(4R,5R)-1'-Benzyl-4-(naphthalen-2-yl)-2-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3i)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.22 (d,  $J$  = 8.3 Hz, 2H), 7.77 (dd,  $J$  = 9.0, 7.9 Hz, 3H), 7.67 (d,  $J$  = 7.9 Hz, 1H), 7.61 (d,  $J$  = 8.6 Hz, 1H), 7.57 – 7.39 (m, 7H), 7.31 (t,  $J$  = 7.4 Hz, 1H), 7.19 (dd,  $J$  = 8.5, 1.6 Hz, 1H), 7.05 – 6.91 (m, 4H), 6.77 (t,  $J$  = 7.7 Hz, 2H), 6.70 – 6.64 (m, 1H), 6.51 (d,  $J$  = 7.5 Hz, 2H), 6.26 – 6.19 (m, 1H), 4.71 (d,  $J$  = 16.0 Hz, 1H), 4.45 (d,  $J$  = 16.0 Hz, 1H), 4.22 (s, 1H), 3.30 (d,  $J$  = 12.6 Hz, 1H), 2.61 (s, 3H), 2.20 (d,  $J$  = 12.6 Hz, 1H).


$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  175.41, 169.03, 152.85, 146.12, 141.64, 139.41, 135.66, 134.64, 133.17, 132.76, 132.26, 130.01, 129.97, 129.86, 129.85, 129.28, 128.90, 128.84, 128.48, 128.31, 128.19, 128.16, 127.65, 127.64, 127.35, 126.64, 126.44, 126.40, 124.30, 123.63, 122.97, 121.32, 109.45, 106.64, 61.27, 47.31, 44.14, 43.84, 22.04.

**HRMS** (ESI) for  $\text{C}_{45}\text{H}_{35}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 715.2261, found 715.2258.

$[\alpha]^{25}_{\text{D}} = +43.25$  ( $c$  = 0.25 in  $\text{CHCl}_3$ ).

**HPLC** analysis: 82 % e.e. (Chiralcel IA, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 13.1 min,  $R_t$  (minor) = 31.2 min.

**(4R,5S)-1'-Benzyl-4-phenyl-2-(*p*-tolyl)-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3j)**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.18 (d,  $J$  = 8.2 Hz, 2H), 7.64 (d,  $J$  = 8.0 Hz, 2H), 7.51 (d,  $J$  = 8.1 Hz, 2H), 7.23 – 7.16 (m, 4H), 7.15 – 7.09 (m, 4H), 7.05 – 6.99 (m, 3H), 6.90 (t,  $J$  = 7.5 Hz, 1H), 6.87 (s, 1H), 6.71 (d,  $J$  = 7.4 Hz, 2H), 6.51 (d,  $J$  = 7.4 Hz, 1H), 6.31 (d,  $J$  = 7.8 Hz, 1H), 4.67 (d,  $J$  = 16.0 Hz, 1H), 4.52 (d,  $J$  = 16.0 Hz, 1H), 4.00 (s, 1H), 3.24 (d,  $J$  = 12.6 Hz, 1H), 2.57 (s, 3H), 2.38 (s, 3H), 2.14 (d,  $J$  = 12.6 Hz, 1H).


$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  175.36, 169.08, 153.11, 146.07, 141.66, 139.01, 138.24, 135.66, 134.93, 134.67, 130.01, 129.93, 129.85, 129.77, 129.52, 128.81, 128.72, 128.48, 127.84, 127.50, 127.36, 126.95, 124.26, 123.63, 122.89, 121.15, 109.30, 105.88, 61.29, 47.30, 43.90, 43.82, 21.98, 21.51.

**HRMS** (ESI) for  $\text{C}_{42}\text{H}_{35}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 679.2261, found 679.2261.

$[\alpha]_D^{25} = +22.75$  ( $c$  = 0.25 in  $\text{CHCl}_3$ ).

**HPLC** analysis: 93 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 9.3 min,  $R_t$  (minor) = 16.4 min.

**(4R,5S)-1'-Benzyl-2-(4-methoxyphenyl)-4-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3k)**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.17 (d,  $J$  = 8.3 Hz, 2H), 7.71 – 7.66 (m, 2H), 7.51 (d,  $J$  = 8.1 Hz, 2H), 7.22 – 7.16 (m, 2H), 7.15 – 7.08 (m, 4H), 7.05 – 6.98 (m, 3H), 6.97 – 6.92 (m, 2H), 6.91 – 6.87 (m, 1H),

6.79 (s, 1H), 6.70 (d,  $J = 7.2$  Hz, 2H), 6.48 (d,  $J = 7.3$  Hz, 1H), 6.31 (d,  $J = 7.8$  Hz, 1H), 4.67 (d,  $J = 16.0$  Hz, 1H), 4.52 (d,  $J = 16.0$  Hz, 1H), 3.98 (s, 1H), 3.85 (s, 3H), 3.24 (d,  $J = 12.6$  Hz, 1H), 2.57 (s, 3H), 2.13 (d,  $J = 12.6$  Hz, 1H).


$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  175.37, 169.14, 159.77, 152.99, 146.07, 141.65, 138.70, 135.65, 134.93, 134.69, 130.00, 129.92, 129.85, 129.76, 128.80, 128.72, 128.47, 127.83, 127.51, 126.95, 125.83, 123.62, 123.07, 122.88, 121.21, 114.29, 109.30, 105.07, 61.35, 55.48, 47.29, 43.88, 43.82, 21.98.

**HRMS** (ESI) for  $\text{C}_{42}\text{H}_{35}\text{N}_2\text{O}_6\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 695.2210, found 695.2213.

$[\alpha]^{25}_{\text{D}} = +27.25$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 81 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 13.5 min,  $R_t$  (minor) = 24.8 min.

**(4R,5S)-1'-Benzyl-2-(4-bromophenyl)-4-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3l)**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.16 (d,  $J = 7.8$  Hz, 2H), 7.74 (d,  $J = 7.9$  Hz, 2H), 7.51 (d,  $J = 7.9$  Hz, 2H), 7.42 (t,  $J = 7.6$  Hz, 2H), 7.32 (t,  $J = 7.2$  Hz, 1H), 7.25 – 7.12 (m, 6H), 7.07 – 6.99 (m, 3H), 6.90 (s, 1H), 6.70 (d,  $J = 7.3$  Hz, 2H), 6.47 (s, 1H), 6.40 (d,  $J = 7.9$  Hz, 1H), 4.64 (d,  $J = 16.0$  Hz, 1H), 4.49 (d,  $J = 16.0$  Hz, 1H), 3.95 (s, 1H), 3.22 (d,  $J = 12.6$  Hz, 1H), 2.58 (s, 3H), 2.11 (d,  $J = 12.6$  Hz, 1H).


$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  175.34, 168.90, 151.76, 146.22, 141.65, 139.79, 135.57, 134.89, 134.47, 132.03, 129.87, 129.86, 129.82, 128.97, 128.89, 128.74, 128.55, 127.94, 127.56, 126.98, 125.77, 123.58, 122.94, 122.21, 121.34, 109.36, 107.17, 61.21, 47.21, 43.87, 43.85, 21.99.

**HRMS** (ESI) for  $\text{C}_{41}\text{H}_{32}\text{BrN}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 743.1210, found 743.1205.

$[\alpha]^{25}_{\text{D}} = +20.50$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 83 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 9.7 min,  $R_t$  (minor) = 29.0 min.

**(4R,5S)-1'-Benzyl-2-(4-chlorophenyl)-4-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-b]azepine-5,3'-indoline]-2',7(6H)-dione (3m)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.17 (d,  $J$  = 7.8 Hz, 2H), 7.68 (d,  $J$  = 8.1 Hz, 2H), 7.52 (d,  $J$  = 7.7 Hz, 2H), 7.39 (d,  $J$  = 8.1 Hz, 2H), 7.24 – 7.08 (m, 6H), 7.07 – 6.97 (m, 3H), 6.95 – 6.86 (m, 2H), 6.72 (d,  $J$  = 6.7 Hz, 2H), 6.50 (d,  $J$  = 7.2 Hz, 1H), 6.32 (d,  $J$  = 7.7 Hz, 1H), 4.66 (d,  $J$  = 15.9 Hz, 1H), 4.53 (d,  $J$  = 15.9 Hz, 1H), 3.99 (s, 1H), 3.24 (d,  $J$  = 12.5 Hz, 1H), 2.58 (s, 3H), 2.15 (d,  $J$  = 12.5 Hz, 1H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  175.34, 168.92, 151.75, 146.22, 141.65, 139.74, 135.58, 134.90, 134.49, 134.03, 129.99, 129.88, 129.82, 129.11, 128.89, 128.74, 128.64, 128.55, 127.94, 127.75, 127.56, 126.98, 125.54, 123.58, 122.94, 121.33, 109.36, 107.07, 61.22, 47.21, 43.86, 43.86, 21.99.

**HRMS** (ESI) for  $\text{C}_{41}\text{H}_{32}\text{ClN}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 699.1715, found 699.1710.

$[\alpha]^{25}_{\text{D}} = +48.50$  ( $c$  = 0.25 in  $\text{CHCl}_3$ ).

**HPLC** analysis: 87 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 10.6 min,  $R_t$  (minor) = 31.4 min.

**(4S,5R)-1'-benzyl-4-phenyl-2-(thiophen-3-yl)-8-tosyl-4,8-dihydrospiro[furo[2,3-b]azepine-5,3'-indoline]-2',7(6H)-dione (3n)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.18 (d,  $J$  = 8.3 Hz, 2H), 7.51 (d,  $J$  = 8.2 Hz, 2H), 7.38 (dd,  $J$  = 3.6, 0.9 Hz, 1H), 7.29 (dd,  $J$  = 5.0, 0.9 Hz, 1H), 7.24 – 7.09 (m, 6H), 7.07 (dd,  $J$  = 5.0, 3.7 Hz, 1H), 7.04-7.00

(m, 3H), 6.91 (t,  $J = 7.5$  Hz, 1H), 6.76 (s, 1H), 6.70 (d,  $J = 6.9$  Hz, 2H), 6.55 (d,  $J = 7.3$  Hz, 1H), 6.31 (d,  $J = 7.8$  Hz, 1H), 4.67 (d,  $J = 16.0$  Hz, 1H), 4.52 (d,  $J = 16.0$  Hz, 1H), 4.02 (s, 1H), 3.23 (d,  $J = 12.6$  Hz, 1H), 2.57 (s, 3H), 2.15 (d,  $J = 12.6$  Hz, 1H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  175.21, 168.82, 148.34, 146.05, 141.55, 138.76, 135.46, 134.78, 134.39, 132.68, 129.84, 129.81, 129.74, 129.70, 128.77, 128.62, 128.43, 127.81, 127.78, 127.42, 126.83, 125.21, 124.03, 123.50, 122.85, 121.17, 109.24, 106.40, 61.05, 47.11, 43.78, 43.72, 21.89.

**HRMS** (ESI) for  $\text{C}_{39}\text{H}_{31}\text{N}_2\text{O}_5\text{S}_2^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 671.1669, found 671.1661.

$[\alpha]^{25}_{\text{D}} = +9.0$ , ( $c = 0.2$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 80 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 11.8 min,  $R_t$  (minor) = 17.3 min.

**(4S,5R)-1'-benzyl-2-(cyclohex-1-en-1-yl)-4-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-b]azepine-5,3'-indoline]-2',7(6H)-dione (3o)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.14 (d,  $J = 8.3$  Hz, 2H), 7.49 (d,  $J = 8.2$  Hz, 2H), 7.23 – 7.05 (m, 6H), 7.02-6.98 (m, 3H), 6.89 (t,  $J = 7.5$  Hz, 1H), 6.69 (d,  $J = 7.0$  Hz, 2H), 6.50-6.48 (m, 2H), 6.41 (s, 1H), 6.29 (d,  $J = 7.8$  Hz, 1H), 4.66 (d,  $J = 16.0$  Hz, 1H), 4.51 (d,  $J = 16.0$  Hz, 1H), 3.95 (s, 1H), 3.18 (d,  $J = 12.5$  Hz, 1H), 2.56 (s, 3H), 2.44-2.37 (m, 1H), 2.29-2.21 (m, 3H), 2.10 (d,  $J = 12.5$  Hz, 1H), 1.80 – 1.62 (m, 4H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  175.24, 169.01, 154.25, 145.87, 141.50, 138.14, 135.53, 134.81, 134.63, 129.91, 129.79, 129.69, 129.61, 128.64, 128.58, 128.30, 127.63, 127.36, 126.80, 126.62, 124.77, 123.49, 122.75, 120.33, 109.14, 104.89, 61.24, 47.14, 43.71, 43.66, 25.28, 24.56, 22.23, 22.10, 21.86.

**HRMS** (ESI) for  $\text{C}_{41}\text{H}_{37}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 669.2418, found 669.2413.

$[\alpha]^{25}_{\text{D}} = +49$ , ( $c = 0.2$  in  $\text{CHCl}_3$ ).

**HPLC analysis:** 82 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 7.9 min,  $R_t$  (minor) = 14.9 min.

**(4R,5R)-1'-Benzyl-2-pentyl-4-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3p)**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.13 (d,  $J$  = 8.2 Hz, 2H), 7.49 (d,  $J$  = 8.1 Hz, 2H), 7.20 – 7.06 (m, 6H), 7.02 – 6.95 (m, 3H), 6.88 (t,  $J$  = 7.5 Hz, 1H), 6.69 (d,  $J$  = 7.3 Hz, 2H), 6.48 (d,  $J$  = 7.4 Hz, 1H), 6.32 (s, 1H), 6.29 (d,  $J$  = 7.8 Hz, 1H), 4.64 (d,  $J$  = 16.0 Hz, 1H), 4.51 (d,  $J$  = 16.0 Hz, 1H), 3.94 (s, 1H), 3.13 (d,  $J$  = 12.5 Hz, 1H), 2.71 (t,  $J$  = 7.7 Hz, 2H), 2.56 (s, 3H), 2.08 (d,  $J$  = 12.5 Hz, 1H), 1.77 – 1.67 (m, 2H), 1.42 – 1.34 (m, 4H), 0.92 (t,  $J$  = 7.0 Hz, 3H).


$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  175.45, 169.24, 156.15, 145.91, 141.66, 138.08, 135.76, 135.00, 134.91, 130.12, 129.94, 129.85, 129.70, 128.72, 128.36, 127.72, 127.50, 126.95, 123.70, 122.87, 119.85, 109.23, 106.98, 61.57, 47.35, 43.86, 43.81, 31.52, 28.58, 27.57, 22.53, 21.98, 14.15.

**HRMS** (ESI) for  $\text{C}_{40}\text{H}_{39}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 659.2574, found 659.2564.

$[\alpha]_D^{25} = +14.5$  ( $c$  = 0.2 in  $\text{CHCl}_3$ ).

**HPLC analysis:** 81 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 6.3 min,  $R_t$  (minor) = 9.8 min.

**(4R,5S)-1'-Benzyl-8-(methylsulfonyl)-2,4-diphenyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3q)**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.69 (d,  $J = 7.5$  Hz, 2H), 7.47 (d,  $J = 7.2$  Hz, 1H), 7.38 (t,  $J = 7.7$  Hz, 2H), 7.29 (t,  $J = 7.4$  Hz, 1H), 7.25 – 7.22 (m, 1H), 7.21 – 7.10 (m, 9H), 6.83 (s, 1H), 6.66 (d,  $J = 7.3$  Hz, 2H), 6.40 (d,  $J = 7.4$  Hz, 1H), 4.78 (d,  $J = 16.0$  Hz, 1H), 4.58 (s, 1H), 4.49 (d,  $J = 16.0$  Hz, 1H), 3.74 (s, 3H), 3.24 (d,  $J = 13.0$  Hz, 1H), 2.58 (d,  $J = 11.9$  Hz, 1H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  175.39, 170.49, 152.51, 141.79, 138.28, 134.96, 134.89, 130.84, 130.09, 129.87, 129.15, 128.83, 128.78, 128.50, 128.30, 127.93, 127.52, 126.89, 124.23, 123.74, 123.51, 121.01, 109.52, 106.97, 59.62, 48.10, 44.39, 43.89, 43.30.

**HRMS** (ESI) for  $\text{C}_{35}\text{H}_{29}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 589.1792, found 589.1792.

$[\alpha]^{25}_{\text{D}} = +58.75$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 89 % ee. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 11.5 min,  $R_t$  (minor) = 28.5 min.

**(4R,5S)-1'-Benzyl-8-((4-bromophenyl)sulfonyl)-2,4-diphenyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3r)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.16 (d,  $J = 8.3$  Hz, 2H), 7.86 (d,  $J = 8.3$  Hz, 2H), 7.74 (d,  $J = 7.7$  Hz, 2H), 7.42 (t,  $J = 7.5$  Hz, 2H), 7.32 (t,  $J = 7.3$  Hz, 1H), 7.21 (dd,  $J = 14.5, 7.4$  Hz, 2H), 7.17 – 7.12 (m, 4H), 7.08 – 7.02 (m, 3H), 7.00 (t,  $J = 7.4$  Hz, 1H), 6.92 (s, 1H), 6.71 (d,  $J = 7.2$  Hz, 2H), 6.65 (d,  $J = 7.2$  Hz, 1H), 6.34 (d,  $J = 7.6$  Hz, 1H), 4.68 (d,  $J = 15.9$  Hz, 1H), 4.53 (d,  $J = 15.9$  Hz, 1H), 4.04 (s, 1H), 3.24 (d,  $J = 12.6$  Hz, 1H), 2.20 (d,  $J = 12.7$  Hz, 1H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  175.25, 169.13, 152.98, 147.09, 141.69, 138.89, 137.43, 134.89, 134.42, 132.54, 131.25, 130.32, 129.98, 129.93, 129.01, 128.89, 128.75, 128.60, 128.44, 127.98, 127.56, 126.98, 124.31, 123.48, 123.18, 121.45, 109.45, 106.72, 61.13, 47.50, 43.89, 43.88.

**HRMS** (ESI) for  $\text{C}_{40}\text{H}_{30}\text{BrN}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 729.1503, found 729.1504.

$[\alpha]^{25}_D = +24.00$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 86 % ee. (Chiralcel IA, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 16.1 min,  $R_t$  (minor) = 23.6 min.

**(4R,5S)-1'-Benzyl-5'-methyl-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3s)**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.18 (d,  $J = 8.1$  Hz, 2H), 7.75 (d,  $J = 7.7$  Hz, 2H), 7.53 (d,  $J = 8.1$  Hz, 2H), 7.41 (t,  $J = 7.6$  Hz, 2H), 7.31 (t,  $J = 7.3$  Hz, 1H), 7.22 (t,  $J = 7.3$  Hz, 1H), 7.19 – 7.15 (m, 1H), 7.12 (d,  $J = 7.6$  Hz, 4H), 7.01 (d,  $J = 7.6$  Hz, 2H), 6.93 (s, 1H), 6.79 (d,  $J = 8.0$  Hz, 1H), 6.70 (d,  $J = 7.4$  Hz, 2H), 6.19 (d,  $J = 7.6$  Hz, 2H), 4.66 (d,  $J = 16.0$  Hz, 1H), 4.51 (d,  $J = 16.0$  Hz, 1H), 3.89 (s, 1H), 3.24 (d,  $J = 12.5$  Hz, 1H), 2.58 (s, 3H), 2.22 (s, 3H), 2.13 (d,  $J = 12.5$  Hz, 1H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  175.25, 169.02, 152.89, 146.02, 139.47, 139.23, 135.81, 135.04, 134.72, 132.27, 130.03, 129.93, 129.89, 129.82, 129.13, 128.82, 128.67, 128.51, 128.28, 127.81, 127.46, 126.96, 124.30, 124.22, 121.16, 109.03, 106.61, 61.35, 47.16, 43.88, 43.81, 22.02, 21.18.

**HRMS** (ESI) for  $\text{C}_{42}\text{H}_{35}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 679.2261, found 679.2253.

$[\alpha]^{25}_D = +24.75$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 91 % e.e. (Chiralcel IA, 20 :80 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 16.5 min,  $R_t$  (minor) = 23.7 min.

**(4R,5S)-1'-Benzyl-7'-methyl-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3t)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.19 (d,  $J = 8.2$  Hz, 2H), 7.73 (d,  $J = 7.5$  Hz, 2H), 7.52 (d,  $J = 8.1$  Hz, 2H), 7.40 (t,  $J = 7.6$  Hz, 2H), 7.32 – 7.27 (m, 1H), 7.26 – 7.23 (m, 1H), 7.32 – 7.10 (m, 5H), 7.07 (d,  $J = 7.5$  Hz, 2H), 6.92 (s, 1H), 6.87 – 6.78 (m, 2H), 6.55 (d,  $J = 6.9$  Hz, 2H), 6.39 (dd,  $J = 6.4, 1.8$  Hz, 1H), 4.93 (d,  $J = 17.1$  Hz, 1H), 4.82 (d,  $J = 17.1$  Hz, 1H), 4.05 (s, 1H), 3.23 (d,  $J = 12.6$  Hz, 1H), 2.58 (s, 3H), 2.14 (d,  $J = 12.6$  Hz, 1H), 1.94 (s, 3H).


$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  176.27, 168.84, 152.72, 146.10, 139.83, 139.38, 137.03, 135.66, 134.83, 132.88, 130.60, 130.10, 130.04, 129.86, 129.78, 128.81, 128.61, 128.24, 127.88, 127.07, 125.41, 124.25, 122.93, 121.61, 121.34, 119.80, 106.68, 60.72, 47.20, 44.99, 44.61, 21.99, 18.43.

**HRMS** (ESI) for  $\text{C}_{42}\text{H}_{35}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 679.2261, found 679.2257.

$[\alpha]_D^{25} = +26.00$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 96 % e.e. (Chiralcel IA, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 15.3 min,  $R_t$  (minor) = 25.1 min.

**(4R,5S)-1'-Benzyl-5',7'-dimethyl-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3u)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.18 (d,  $J = 7.0$  Hz, 2H), 7.73 (d,  $J = 6.8$  Hz, 2H), 7.53 (d,  $J = 7.1$  Hz, 2H), 7.44 – 7.37 (m, 2H), 7.34 – 7.27 (m, 2H), 7.21 – 7.09 (m, 5H), 7.05 (d,  $J = 6.6$  Hz, 2H), 6.90 (s, 1H), 6.60 (s, 1H), 6.56 (d,  $J = 5.6$  Hz, 2H), 6.08 (s, 1H), 4.91 (d,  $J = 17.2$  Hz, 1H), 4.80 (d,  $J = 16.9$  Hz, 1H), 3.93 (s, 1H), 3.22 (d,  $J = 12.3$  Hz, 1H), 2.58 (s, 3H), 2.19 (s, 3H), 2.12 (d,  $J = 11.8$  Hz, 1H), 1.88 (s, 3H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  176.21, 168.85, 152.82, 145.98, 139.43, 137.36, 137.12, 135.88, 134.98, 133.37, 132.20, 130.61, 130.08, 129.95, 129.85, 128.81, 128.78, 128.64, 128.24, 127.82, 127.05, 125.47, 124.29, 122.18, 121.31, 119.43, 106.70, 60.88, 47.12, 44.94, 44.61, 22.04, 20.88, 18.27.

**HRMS** (ESI) for  $\text{C}_{43}\text{H}_{37}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 693.2418, found 693.2415.

$[\alpha]^{25}_{\text{D}} = +18.50$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 76 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 7.1 min,  $R_t$  (minor) = 13.1 min.

**(4R,5S)-1'-Benzyl-5'-methoxy-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3v)**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.16 (d,  $J = 8.2$  Hz, 2H), 7.75 (d,  $J = 7.5$  Hz, 2H), 7.50 (d,  $J = 8.1$  Hz, 2H), 7.41 (t,  $J = 7.7$  Hz, 2H), 7.31 (t,  $J = 7.4$  Hz, 1H), 7.23 (t,  $J = 7.4$  Hz, 1H), 7.20 – 7.10 (m, 5H), 7.07 (d,  $J = 7.5$  Hz, 2H), 6.92 (s, 1H), 6.70 (d,  $J = 7.3$  Hz, 2H), 6.51 (dd,  $J = 8.5, 2.4$  Hz, 1H), 6.20 (d,  $J = 8.5$  Hz, 1H), 6.11 (d,  $J = 2.2$  Hz, 1H), 4.66 (d,  $J = 16.0$  Hz, 1H), 4.51 (d,  $J = 16.0$  Hz, 1H), 3.94 (s, 1H), 3.70 (s, 3H), 3.25 (d,  $J = 12.6$  Hz, 1H), 2.56 (s, 3H), 2.15 (d,  $J = 12.6$  Hz, 1H).


$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  175.05, 169.02, 156.15, 152.85, 146.30, 139.44, 135.61, 135.01, 134.93, 134.67, 131.21, 130.03, 129.92, 129.87, 129.75, 128.82, 128.69, 128.55, 128.27, 127.87, 127.48, 126.95, 124.30, 121.16, 112.97, 111.19, 109.67, 106.61, 61.66, 55.83, 47.30, 43.89, 43.87, 21.97.

**HRMS** (ESI) for  $\text{C}_{42}\text{H}_{35}\text{N}_2\text{O}_6\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 695.2210, found 695.2210.

$[\alpha]^{25}_{\text{D}} = +26.50$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 81% e.e. (Chiralcel IA, 20 :80 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 22.3 min,  $R_t$  (minor) = 28.1 min.

**(4R,5S)-1'-Benzyl-5'-bromo-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3w)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.14 (d,  $J$  = 8.2 Hz, 2H), 7.76 (d,  $J$  = 7.5 Hz, 2H), 7.56 (d,  $J$  = 8.1 Hz, 2H), 7.42 (t,  $J$  = 7.6 Hz, 2H), 7.32 (t,  $J$  = 7.3 Hz, 1H), 7.25 – 7.09 (m, 7H), 6.96 (d,  $J$  = 7.5 Hz, 2H), 6.90 (s, 1H), 6.69 (d,  $J$  = 7.2 Hz, 2H), 6.37 (d,  $J$  = 1.1 Hz, 1H), 6.16 (d,  $J$  = 8.3 Hz, 1H), 4.62 (d,  $J$  = 16.0 Hz, 1H), 4.52 (d,  $J$  = 16.0 Hz, 1H), 3.67 (s, 1H), 3.24 (d,  $J$  = 12.5 Hz, 1H), 2.61 (s, 3H), 2.14 (d,  $J$  = 12.5 Hz, 1H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  174.73, 168.81, 153.17, 146.58, 140.67, 139.59, 135.31, 134.38, 134.20, 131.78, 130.18, 129.91, 129.78, 129.73, 128.86, 128.82, 128.70, 128.41, 128.07, 127.74, 126.91, 126.72, 124.35, 120.66, 115.63, 110.78, 106.46, 61.37, 47.14, 43.88, 43.51, 22.24.

**HRMS** (ESI) for  $\text{C}_{41}\text{H}_{32}\text{BrN}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 743.1210, found 743.1198.

$[\alpha]_D^{25} = +16.00$  ( $c$  = 0.25 in  $\text{CHCl}_3$ ).

**HPLC** analysis: 76 % e.e. (Chiralcel IA, 20 :80 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 18.8 min,  $R_t$  (minor) = 22.1 min.

**(4R,5S)-1'-Benzyl-6'-bromo-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3x)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.16 (d,  $J$  = 8.0 Hz, 2H), 7.74 (d,  $J$  = 7.8 Hz, 2H), 7.51 (d,  $J$  = 8.0 Hz, 2H), 7.42 (t,  $J$  = 7.6 Hz, 2H), 7.32 (t,  $J$  = 7.3 Hz, 1H), 7.25 – 7.12 (m, 6H), 7.03 (t,  $J$  = 8.5 Hz, 3H), 6.90 (s, 1H), 6.70 (d,  $J$  = 7.3 Hz, 2H), 6.47 (s, 1H), 6.40 (d,  $J$  = 8.0 Hz, 1H), 4.64 (d,  $J$  = 16.0 Hz, 1H), 4.49 (d,  $J$  = 16.0 Hz, 1H), 3.95 (s, 1H), 3.22 (d,  $J$  = 12.6 Hz, 1H), 2.57 (s, 3H), 2.11 (d,  $J$  = 12.6 Hz, 1H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  175.23, 168.81, 152.97, 146.24, 143.05, 139.37, 135.56, 134.32, 134.27, 129.94, 129.88, 129.85, 129.81, 128.98, 128.90, 128.87, 128.72, 128.39, 128.11, 127.78, 126.90, 125.84, 124.94, 124.31, 122.59, 121.01, 112.63, 106.53, 61.01, 47.12, 43.93, 43.82, 22.02.

**HRMS** (ESI) for  $\text{C}_{41}\text{H}_{32}\text{BrN}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 743.1210, found 743.1204.

$[\alpha]^{25}_{\text{D}} = +37.25$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 90 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 8.5 min,  $R_t$  (minor) = 17.2 min.

**(4R,5S)-1'-Benzyl-5'-chloro-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3y)**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.15 (d,  $J = 8.3$  Hz, 2H), 7.80 – 7.73 (m, 2H), 7.55 (d,  $J = 8.1$  Hz, 2H), 7.42 (t,  $J = 7.8$  Hz, 2H), 7.32 (t,  $J = 7.4$  Hz, 1H), 7.23 (t,  $J = 7.4$  Hz, 1H), 7.21 – 7.10 (m, 5H), 7.01 – 6.94 (m, 3H), 6.90 (s, 1H), 6.68 (d,  $J = 7.2$  Hz, 2H), 6.19 (dd,  $J = 6.8, 5.2$  Hz, 2H), 4.62 (d,  $J = 16.1$  Hz, 1H), 4.52 (d,  $J = 16.1$  Hz, 1H), 3.73 (s, 1H), 3.25 (d,  $J = 12.6$  Hz, 1H), 2.60 (s, 3H), 2.14 (d,  $J = 12.6$  Hz, 1H).


$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  174.85, 168.77, 153.17, 146.64, 140.21, 139.65, 135.42, 134.44, 134.27, 131.50, 130.11, 129.94, 129.83, 129.82, 128.87, 128.83, 128.70, 128.41, 128.33, 128.07, 127.73, 126.91, 124.37, 124.04, 120.70, 110.29, 106.45, 61.42, 47.17, 43.93, 43.55, 22.14.

**HRMS** (ESI) for  $\text{C}_{41}\text{H}_{32}\text{ClN}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 699.1715, found 699.1714.

$[\alpha]^{25}_{\text{D}} = +24.25$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 82 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 9.8 min,  $R_t$  (minor) = 22.8 min.

**(4R,5S)-1'-Benzyl-5'-fluoro-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3z)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.17 (d,  $J$  = 8.0 Hz, 2H), 7.76 (d,  $J$  = 7.5 Hz, 2H), 7.54 (d,  $J$  = 8.0 Hz, 2H), 7.42 (t,  $J$  = 7.5 Hz, 2H), 7.35 – 7.29 (m, 1H), 7.23 (d,  $J$  = 7.3 Hz, 1H), 7.21 – 7.09 (m, 5H), 7.03 (d,  $J$  = 7.4 Hz, 2H), 6.91 (s, 1H), 6.80 – 6.60 (m, 3H), 6.19 (dd,  $J$  = 8.4, 3.9 Hz, 1H), 5.95 (d,  $J$  = 7.7 Hz, 1H), 4.64 (d,  $J$  = 16.0 Hz, 1H), 4.51 (d,  $J$  = 16.0 Hz, 1H), 3.85 (s, 1H), 3.26 (d,  $J$  = 12.6 Hz, 1H), 2.58 (s, 3H), 2.14 (d,  $J$  = 12.6 Hz, 1H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  175.04, 168.85, 153.12, 146.73, 139.63, 137.58, 135.49, 134.59, 134.35, 131.63 – 131.42 (m), 129.96, 129.87, 128.87, 128.81, 128.68, 128.41, 128.08, 127.67, 126.90, 124.36, 120.86, 115.35, 115.12, 111.90, 111.65, 110.01, 109.93, 106.46, 61.59, 47.25, 43.95, 43.60, 21.93.

**HRMS** (ESI) for  $\text{C}_{41}\text{H}_{32}\text{FN}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 683.2010, found 683.2004.

$[\alpha]^{25}_{\text{D}} = +1.25$  ( $c$  = 0.25 in  $\text{CHCl}_3$ ).

**HPLC** analysis: 80% e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 9.3 min,  $R_t$  (minor) = 20.0 min.

**(4R,5S)-1'-Methyl-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3aa)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.16 (d,  $J$  = 8.2 Hz, 2H), 7.75 (d,  $J$  = 7.4 Hz, 2H), 7.50 (d,  $J$  = 8.1 Hz, 2H), 7.41 (t,  $J$  = 7.6 Hz, 2H), 7.31 (t,  $J$  = 7.4 Hz, 1H), 7.16 – 7.07 (m, 4H), 6.92 (t,  $J$  = 7.3 Hz, 3H), 6.88 (s, 1H), 6.56 (d,  $J$  = 7.4 Hz, 1H), 6.42 (d,  $J$  = 7.8 Hz, 1H), 3.86 (s, 1H), 3.21 (d,  $J$  = 12.6 Hz, 1H), 2.82 (s, 3H), 2.57 (s, 3H), 2.15 (d,  $J$  = 12.6 Hz, 1H).


$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  175.13, 169.49, 152.82, 146.10, 142.30, 139.32, 135.55, 134.29, 130.07, 130.04, 129.80, 129.77, 129.48, 128.83, 128.27, 128.03, 127.91, 124.27, 123.50, 122.91, 120.94, 107.88, 106.51, 61.26, 48.07, 42.84, 25.99, 21.99.

**HRMS** (ESI) for  $\text{C}_{35}\text{H}_{29}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 589.1792, found 589.1794

$[\alpha]^{25}_{\text{D}} = +0.75$  ( $c = 0.25$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 95 % e.e. (Chiralcel IA, 20:80 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 11.2 min,  $R_t$  (minor) = 17.9 min.

**(4*S*,5*R*)-1'-allyl-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6*H*)-dione (3ab)**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.17 (d,  $J = 8.1$  Hz, 2H), 7.75 (d,  $J = 7.6$  Hz, 2H), 7.51 (d,  $J = 8.0$  Hz, 1H), 7.41 (t,  $J = 7.6$  Hz, 1H), 7.31 (t,  $J = 7.3$  Hz, 1H), 7.12 (dt,  $J = 15.1, 8.2$  Hz, 2H), 6.99 (d,  $J = 7.0$  Hz, 1H), 6.96 – 6.88 (m, 1H), 6.53 (d,  $J = 7.4$  Hz, 1H), 6.46 (d,  $J = 7.8$  Hz, 1H), 5.43 – 5.23 (m, 1H), 4.96 (d,  $J = 10.4$  Hz, 1H), 4.65 (d,  $J = 17.2$  Hz, 1H), 4.17 (dd,  $J = 16.4, 4.3$  Hz, 1H), 3.94 (s, 1H), 3.86 (dd,  $J = 16.4, 5.2$  Hz, 1H), 3.20 (d,  $J = 12.6$  Hz, 1H), 2.57 (s, 1H), 2.13 (d,  $J = 12.6$  Hz, 1H).


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  174.79, 169.10, 152.69, 146.00, 141.56, 139.28, 135.51, 134.34, 130.47, 129.88, 129.73, 129.67, 128.72, 128.66, 128.20, 127.76, 124.17, 123.48, 122.74, 120.98, 117.68, 108.94, 106.46, 61.01, 47.48, 43.34, 42.25, 21.88.

**HRMS** (ESI) for  $\text{C}_{37}\text{H}_{31}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 615.1948, found 615.1949.

$[\alpha]^{25}_{\text{D}} = +15$ , ( $c = 0.1$  in  $\text{CHCl}_3$ ).

**HPLC** analysis: 81 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 7.9 min,  $R_t$  (minor) = 13.4 min.

**(3R,3'S)-1''-Benzyl-3',5-diphenyl-1'-tosyl-2H-dispiro[furan-3,2'-piperidine-4',3''-indoline]-  
2,2'',6'-trione (4a)**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.05 (d,  $J$  = 8.0 Hz, 2H), 7.42 (d,  $J$  = 6.3 Hz, 2H), 7.37 – 7.28 (m, 10H), 7.07 (d,  $J$  = 7.4 Hz, 1H), 7.01 (t,  $J$  = 7.4 Hz, 2H), 6.94 (d,  $J$  = 6.4 Hz, 1H), 6.89 (dd,  $J$  = 14.5, 7.2 Hz, 2H), 6.84 (s, 1H), 6.76 (d,  $J$  = 7.2 Hz, 1H), 6.61 (d,  $J$  = 7.7 Hz, 1H), 6.55 (t,  $J$  = 7.0 Hz, 1H), 4.99 (d,  $J$  = 15.2 Hz, 1H), 4.84 (d,  $J$  = 15.3 Hz, 1H), 4.05 (s, 1H), 3.03 (d,  $J$  = 16.9 Hz, 1H), 2.71 (d,  $J$  = 17.0 Hz, 1H), 2.44 (s, 3H).

$^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ )  $\delta$  176.97, 167.67, 154.27, 145.20, 142.09, 136.11, 135.16, 132.31, 131.03, 130.27, 129.86, 129.30, 129.11, 129.05, 128.99, 128.60, 128.51, 128.11, 127.92, 127.84, 127.69, 127.06, 125.49, 123.36, 122.97, 109.48, 103.34, 72.32, 57.17, 49.98, 44.28, 43.51, 21.88.

**HRMS** (ESI) for  $\text{C}_{41}\text{H}_{33}\text{N}_2\text{O}_5\text{S}^+$   $[\text{M}+\text{H}]^+$   $m/z$ : calcd 681.2054, found 681.2055.




$[\alpha]^{25}_{\text{D}} = +5.00$  ( $c$  = 0.25 in  $\text{CHCl}_3$ ).




**HPLC** analysis: 92 % e.e. (Chiralcel OD-H, 25 :75 *i*PrOH/Hexane, 1.0 mL/min),  $R_t$  (major) = 22.3 min,  $R_t$  (minor) = 33.0 min.




## 6. References.




- [1] (a) G. Q. Yang, Y.-M. Ke and Y. Zhao, *Angew. Chem., Int. Ed.* 2021, **60**, 12775–12780; (b) Y. Luo, K.-M. Qiu, X. Lu, K. Liu, J. Fu and H.-L. Zhu, *Bioorg. Med. Chem.* 2011, **19**, 4730–4738.
- [2] T. Mukaiyama, K. Ogata, I. Sato and Y. Hayashi, *Chem. Eur. J.* 2014, **20**, 13583–13588.




## 7. $^1\text{H}$ NMR, $^{13}\text{C}$ NMR and HPLC Spectra of the Compounds.













































**3k**










**31**














**3m**









































































**(4R,5R)-1'-Benzyl-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3a)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 9.553    | 5933240  | 175662 | 50.796  | 67.355  |
| 2     | 15.761   | 5747282  | 85137  | 49.204  | 32.645  |
| Total |          | 11680522 | 260798 | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 9.873    | 7354986 | 223637 | 98.261  | 99.068  |
| 2     | 16.366   | 130164  | 2105   | 1.739   | 0.932   |
| Total |          | 7485150 | 225742 | 100.000 | 100.000 |

**(4R,5R)-1'-Benzyl-2-phenyl-4-(p-tolyl)-8-tosyl-4,8-dihydrospiro[furo[2,3-b]azepine-5,3'-indoline]-2',7(6H)-dione (3b)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 9.528    | 5404251  | 146005 | 50.019  | 60.130  |
| 2     | 13.350   | 5400061  | 96812  | 49.981  | 39.870  |
| Total |          | 10804312 | 242817 | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 9.495    | 11041873 | 307387 | 93.121  | 94.961  |
| 2     | 13.463   | 815623   | 16310  | 6.879   | 5.039   |
| Total |          | 11857495 | 323697 | 100.000 | 100.000 |

**(4R,5R)-1'-Benzyl-2-phenyl-4-(m-tolyl)-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3c)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 12.394   | 1605531 | 49110  | 51.010  | 70.728  |
| 2     | 27.933   | 1541937 | 20325  | 48.990  | 29.272  |
| Total |          | 3147468 | 69435  | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 12.357   | 8816402 | 263172 | 89.228  | 94.941  |
| 2     | 27.950   | 1064310 | 14023  | 10.772  | 5.059   |
| Total |          | 9880711 | 277194 | 100.000 | 100.000 |

**(4R,5R)-1'-Benzyl-2-phenyl-4-(o-tolyl)-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3d)**



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 12.080   | 4126142 | 132331 | 49.975  | 66.856  |
| 2     | 22.778   | 4130264 | 65604  | 50.025  | 33.144  |
| Total |          | 8256406 | 197935 | 100.000 | 100.000 |




PDA Ch1 254nm

| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 12.096   | 1750959 | 55857  | 92.476  | 95.642  |
| 2     | 22.725   | 142466  | 2545   | 7.524   | 4.358   |
| Total |          | 1893425 | 58403  | 100.000 | 100.000 |

**(4R,5R)-1'-Benzyl-4-(3-methoxyphenyl)-2-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3e)**




mAU



PDA Ch1 254nm

| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 13.750   | 1918953 | 58002  | 50.577  | 65.746  |
| 2     | 23.535   | 1875200 | 30220  | 49.423  | 34.254  |
| Total |          | 3794153 | 88222  | 100.000 | 100.000 |



mAU



PDA Ch1 254nm


| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 13.657   | 17259226 | 507326 | 96.784  | 98.192  |
| 2     | 23.733   | 573410   | 9344   | 3.216   | 1.808   |
| Total |          | 17832636 | 516670 | 100.000 | 100.000 |

**(4R,5R)-1'-Benzyl-4-(4-chlorophenyl)-2-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3f)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 10.692   | 6831769  | 146001 | 51.537  | 64.122  |
| 2     | 16.433   | 6424240  | 81691  | 48.463  | 35.878  |
| Total |          | 13256009 | 227693 | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 10.797   | 8226203 | 191090 | 94.421  | 92.036  |
| 2     | 17.430   | 486036  | 16535  | 5.579   | 7.964   |
| Total |          | 8712239 | 207625 | 100.000 | 100.000 |

**(4R,5R)-1'-Benzyl-2-phenyl-8-tosyl-4-(4-(trifluoromethyl)phenyl)-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3g)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 10.806   | 6063356  | 232297 | 51.584  | 76.191  |
| 2     | 29.655   | 5691010  | 72591  | 48.416  | 23.809  |
| Total |          | 11754366 | 304889 | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 9.924    | 24820230 | 954144 | 92.924  | 97.231  |
| 2     | 28.708   | 1890064  | 27177  | 7.076   | 2.769   |
| Total |          | 26710295 | 981321 | 100.000 | 100.000 |

**(4R,5R)-1'-Benzyl-4-(4-nitrophenyl)-2-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3h)**



PDA Ch1 254nm


| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 22.028   | 31726231 | 244309 | 48.780  | 55.674  |
| 2     | 27.713   | 33313453 | 194511 | 51.220  | 44.326  |
| Total |          | 65039684 | 438820 | 100.000 | 100.000 |




PDA Ch1 254nm

| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 22.661   | 2776332 | 25671  | 92.442  | 92.902  |
| 2     | 28.730   | 227002  | 1961   | 7.558   | 7.098   |
| Total |          | 3003334 | 27633  | 100.000 | 100.000 |

**(4R,5R)-1'-Benzyl-4-(naphthalen-2-yl)-2-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3i)**




mAU



PDA Ch1 254nm

| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 13.113   | 9391695  | 267582 | 49.756  | 71.315  |
| 2     | 31.387   | 9483937  | 107631 | 50.244  | 28.685  |
| Total |          | 18875632 | 375213 | 100.000 | 100.000 |



mAU



PDA Ch1 254nm


| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 13.059   | 19212850 | 532654 | 91.592  | 96.098  |
| 2     | 31.169   | 1763722  | 21628  | 8.408   | 3.902   |
| Total |          | 20976572 | 554282 | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-4-phenyl-2-(p-tolyl)-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3j)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 9.391    | 928820  | 26761  | 51.495  | 69.522  |
| 2     | 16.347   | 874889  | 11732  | 48.505  | 30.478  |
| Total |          | 1803708 | 38493  | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 9.329    | 3709148 | 106860 | 96.526  | 98.234  |
| 2     | 16.403   | 133509  | 1921   | 3.474   | 1.766   |
| Total |          | 3842657 | 108782 | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-2-(4-methoxyphenyl)-4-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3k)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 13.386   | 22303608 | 392024 | 50.488  | 68.423  |
| 2     | 23.877   | 21872849 | 180914 | 49.512  | 31.577  |
| Total |          | 44176457 | 572938 | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 13.532   | 9030954 | 163064 | 90.638  | 95.482  |
| 2     | 24.769   | 932853  | 7717   | 9.362   | 4.518   |
| Total |          | 9963807 | 170781 | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-2-(4-bromophenyl)-4-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3l)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 9.793    | 1803208 | 46520  | 51.038  | 80.935  |
| 2     | 28.859   | 1729861 | 10959  | 48.962  | 19.065  |
| Total |          | 3533069 | 57479  | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 9.731    | 7108721 | 184176 | 91.433  | 97.475  |
| 2     | 29.037   | 666031  | 4772   | 8.567   | 2.525   |
| Total |          | 7774752 | 188948 | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-2-(4-chlorophenyl)-4-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3m)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 10.478   | 3413485 | 85673  | 53.750  | 83.144  |
| 2     | 34.365   | 2937215 | 17368  | 46.250  | 16.856  |
| Total |          | 6350700 | 103042 | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 10.618   | 3543228 | 68589  | 93.133  | 97.082  |
| 2     | 31.377   | 261242  | 2062   | 6.867   | 2.918   |
| Total |          | 3804471 | 70650  | 100.000 | 100.000 |

**(4S,5R)-1'-benzyl-4-phenyl-2-(thiophen-3-yl)-8-tosyl-4,8-dihydrospiro[furo[2,3-b]azepine-5,3'-indoline]-2',7(6H)-dione (3n)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 11.748   | 1836942 | 33655  | 52.682  | 65.216  |
| 2     | 17.086   | 1649895 | 17950  | 47.318  | 34.784  |
| Total |          | 3486837 | 51606  | 100.000 | 100.000 |



PDA Ch1 254nm

| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 11.820   | 6686979 | 144208 | 89.841  | 93.863  |
| 2     | 17.357   | 756173  | 9429   | 10.159  | 6.137   |
| Total |          | 7443152 | 153637 | 100.000 | 100.000 |


**(4S,5R)-1'-benzyl-2-(cyclohex-1-en-1-yl)-4-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-b]azepine-5,3'-indoline]-2',7(6H)-dione (3o)**



PDA Ch1 254nm

| Peak# | Ret.Time | Area     | Height  | Area%   | Height% |
|-------|----------|----------|---------|---------|---------|
| 1     | 7.893    | 24408219 | 781629  | 50.661  | 69.063  |
| 2     | 14.518   | 23771590 | 350130  | 49.339  | 30.937  |
| Total |          | 48179809 | 1131759 | 100.000 | 100.000 |


mAU




PDA Ch1 254nm

| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 7.898    | 20377872 | 677616 | 90.959  | 95.936  |
| 2     | 14.902   | 2025399  | 28708  | 9.041   | 4.064   |
| Total |          | 22403271 | 706324 | 100.000 | 100.000 |

**(4R,5R)-1'-Benzyl-2-pentyl-4-phenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3p)**




mAU



PDA Ch1 254nm

| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 6.407    | 5060091  | 157600 | 49.888  | 55.310  |
| 2     | 9.720    | 5082889  | 127341 | 50.112  | 44.690  |
| Total |          | 10142979 | 284941 | 100.000 | 100.000 |



mAU



PDA Ch1 254nm


| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 6.344    | 16554011 | 700602 | 89.814  | 91.815  |
| 2     | 9.755    | 1877420  | 62460  | 10.186  | 8.185   |
| Total |          | 18431430 | 763062 | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-8-(methylsulfonyl)-2,4-diphenyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3q)**



PDA Ch1 254nm


| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 11.521   | 12023548 | 421835 | 50.023  | 73.521  |
| 2     | 28.092   | 12012595 | 151930 | 49.977  | 26.479  |
| Total |          | 24036144 | 573765 | 100.000 | 100.000 |




PDA Ch1 254nm

| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 11.517   | 11697782 | 410816 | 94.657  | 97.760  |
| 2     | 28.524   | 660237   | 9414   | 5.343   | 2.240   |
| Total |          | 12358019 | 420230 | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-8-((4-bromophenyl)sulfonyl)-2,4-diphenyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3r)**




mAU



PDA Ch1 254nm

| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 16.179   | 2028336 | 52727  | 49.596  | 60.784  |
| 2     | 23.681   | 2061353 | 34019  | 50.404  | 39.216  |
| Total |          | 4089689 | 86746  | 100.000 | 100.000 |


mAU




PDA Ch1 254nm

| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 16.123   | 4741988 | 123625 | 92.819  | 95.036  |
| 2     | 23.636   | 366857  | 6458   | 7.181   | 4.964   |
| Total |          | 5108845 | 130083 | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-5'-methyl-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-b]azepine-5,3'-indoline]-2',7(6H)-dione (3s)**




mAU



PDA Ch1 254nm

| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 16.782   | 2340988 | 60650  | 53.725  | 63.253  |
| 2     | 22.473   | 2016361 | 35235  | 46.275  | 36.747  |
| Total |          | 4357349 | 95885  | 100.000 | 100.000 |



mAU



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 16.542   | 1180948 | 26880  | 95.679  | 96.527  |
| 2     | 23.745   | 53339   | 967    | 4.321   | 3.473   |
| Total |          | 1234287 | 27847  | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-7'-methyl-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-b]azepine-5,3'-indoline]-2',7(6H)-dione (3t)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 7.779    | 6285914  | 164150 | 53.249  | 66.624  |
| 2     | 13.591   | 5518815  | 82233  | 46.751  | 33.376  |
| Total |          | 11804730 | 246383 | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 7.788    | 15867537 | 478941 | 96.432  | 98.173  |
| 2     | 13.788   | 587172   | 8915   | 3.568   | 1.827   |
| Total |          | 16454709 | 487857 | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-5',7'-dimethyl-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-b]azepine-5,3'-indoline]-2',7(6H)-dione (3u)**



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 7.100    | 4016555 | 165985 | 50.953  | 73.876  |
| 2     | 13.074   | 3866361 | 58695  | 49.047  | 26.124  |
| Total |          | 7882916 | 224680 | 100.000 | 100.000 |




PDA Ch1 254nm

| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 7.052    | 17854805 | 708614 | 88.014  | 95.149  |
| 2     | 13.092   | 2431593  | 36131  | 11.986  | 4.851   |
| Total |          | 20286398 | 744745 | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-5'-methoxy-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3v)**




mAU



PDA Ch1 254nm

| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 22.466   | 1702556 | 27648  | 51.796  | 56.677  |
| 2     | 28.087   | 1584455 | 21133  | 48.204  | 43.323  |
| Total |          | 3287011 | 48782  | 100.000 | 100.000 |


mAU




PDA Ch1 254nm

| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 22.299   | 5538319 | 87042  | 90.691  | 92.025  |
| 2     | 28.137   | 568449  | 7543   | 9.309   | 7.975   |
| Total |          | 6106767 | 94585  | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-5'-bromo-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3w)**




mAU



PDA Ch1 254nm

| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 18.423   | 6914818  | 140880 | 50.595  | 56.113  |
| 2     | 21.608   | 6752257  | 110183 | 49.405  | 43.887  |
| Total |          | 13667075 | 251064 | 100.000 | 100.000 |



mAU



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 18.822   | 2410617 | 47919  | 88.020  | 89.182  |
| 2     | 22.063   | 328105  | 5813   | 11.980  | 10.818  |
| Total |          | 2738721 | 53732  | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-6'-bromo-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3x)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 8.561    | 2014304 | 65930  | 50.248  | 73.349  |
| 2     | 17.244   | 1994405 | 23955  | 49.752  | 26.651  |
| Total |          | 4008708 | 89886  | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 8.496    | 6294471 | 212856 | 95.073  | 98.141  |
| 2     | 17.210   | 326174  | 4031   | 4.927   | 1.859   |
| Total |          | 6620645 | 216887 | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-5'-chloro-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3y)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 9.294    | 977540  | 32488  | 51.588  | 76.542  |
| 2     | 21.332   | 917362  | 9957   | 48.412  | 23.458  |
| Total |          | 1894902 | 42445  | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 9.832    | 4670232 | 140784 | 90.958  | 96.894  |
| 2     | 22.792   | 464238  | 4513   | 9.042   | 3.106   |
| Total |          | 5134470 | 145297 | 100.000 | 100.000 |

**(4R,5S)-1'-Benzyl-5'-fluoro-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3z)**



PDA Ch1 254nm



| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 9.201    | 1491494 | 50571  | 50.596  | 77.073  |
| 2     | 19.884   | 1456377 | 15043  | 49.404  | 22.927  |
| Total |          | 2947871 | 65615  | 100.000 | 100.000 |



PDA Ch1 254nm


| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 9.278    | 4657303 | 157903 | 89.970  | 96.380  |
| 2     | 19.998   | 519177  | 5931   | 10.030  | 3.620   |
| Total |          | 5176480 | 163834 | 100.000 | 100.000 |

**(4R,5S)-1'-Methyl-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-*b*]azepine-5,3'-indoline]-2',7(6H)-dione (3aa)**



PDA Ch1 254nm


| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 11.129   | 16140191 | 560660 | 49.848  | 61.564  |
| 2     | 17.805   | 16238325 | 350038 | 50.152  | 38.436  |
| Total |          | 32378516 | 910698 | 100.000 | 100.000 |




PDA Ch1 254nm

| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 11.162   | 5560281 | 196003 | 97.304  | 98.507  |
| 2     | 17.857   | 154031  | 2971   | 2.696   | 1.493   |
| Total |          | 5714312 | 198974 | 100.000 | 100.000 |

**(4S,5R)-1'-allyl-2,4-diphenyl-8-tosyl-4,8-dihydrospiro[furo[2,3-b]azepine-5,3'-indoline]-2',7(6H)-dione (3ab)**




mAU



PDA Ch1 254nm

| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 8.107    | 3386526 | 59571  | 51.977  | 66.301  |
| 2     | 13.339   | 3128889 | 30278  | 48.023  | 33.699  |
| Total |          | 6515415 | 89849  | 100.000 | 100.000 |


mAU




PDA Ch1 254nm

| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 7.916    | 17264998 | 399535 | 90.411  | 95.287  |
| 2     | 13.422   | 1831119  | 19763  | 9.589   | 4.713   |
| Total |          | 19096117 | 419299 | 100.000 | 100.000 |

**(3R,3'S)-1''-Benzyl-3',5-diphenyl-1'-tosyl-2H-dispiro[furan-3,2'-piperidine-4',3''-indoline]-2,2'',6'-trione (4a)**




mAU



PDA Ch1 254nm

| Peak# | Ret.Time | Area     | Height | Area%   | Height% |
|-------|----------|----------|--------|---------|---------|
| 1     | 23.007   | 17091847 | 132702 | 52.510  | 61.738  |
| 2     | 31.449   | 15458006 | 82242  | 47.490  | 38.262  |
| Total |          | 32549854 | 214944 | 100.000 | 100.000 |

mAU



PDA Ch1 254nm

| Peak# | Ret.Time | Area    | Height | Area%   | Height% |
|-------|----------|---------|--------|---------|---------|
| 1     | 23.266   | 9282406 | 70612  | 95.472  | 95.981  |
| 2     | 33.017   | 440240  | 2957   | 4.528   | 4.019   |
| Total |          | 9722647 | 73569  | 100.000 | 100.000 |